4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 7.5% Following Analyst Upgrade

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) shares traded up 7.5% on Friday after Bank of America raised their price target on the stock from $28.00 to $33.00. The stock traded as high as $21.29 and last traded at $20.99. 73,528 shares were traded during trading, a decline of 85% from the average session […]

Related Keywords

United States ,America ,Jacob Chacko ,Scott Bizily ,D Molecular Therapeutics Inc ,Arrowmark Colorado Holdings ,Geode Capital Management ,Nasdaq ,Molecular Therapeutics ,Get Rating ,Director Jacob Chacko ,Street Corp ,Capital Management ,Mark Colorado Holdings ,Sigma Advisers ,Two Sigma Investments ,Sigma Investments ,Molecular Therapeutics Price ,Molecular Therapeutics Daily ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Stocks ,Technicals ,